Immune Network Ltd., advises the company has a plan to acquire patented oral vaccine technology developed and clinically validated by the privately-held Immunitor group of companies and affiliates. As a pre-condition of this acquisition, the company will need to update its regulatory filings and deal with outstanding accounting and legal issues, in addition to full due-diligence analysis of the respective companies.

Immunitor's technology is based on decades of research and is positioned to forever change the way vaccines are made and administered. The acquisition will give Immune Network an exciting opportunity to commercialize existing oral vaccines for high-impact infectious diseases such as influenza, tuberculosis, hepatitis and HIV. The acquisition will additionally give Immune Network access to Immunitor's existing manufactured line of orally administered, broad-spectrum, prophylactic and therapeutic tableted vaccines designed to protect against microbial and fungal infections and for immunotherapy of non-infectious diseases such as cancer and autoimmune and/or metabolic disorders comprising allergy, diabetes, obesity and atherosclerosis. Immunitor's advanced innovative technology can dramatically shorten vaccine production timelines and offers tremendous potential to improve and protect human health globally.